Dubowchik G M, Mosure K, Knipe J O, Firestone R A
Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, CT 06492-7660, USA.
Bioorg Med Chem Lett. 1998 Dec 1;8(23):3347-52. doi: 10.1016/s0960-894x(98)00610-6.
Substrates containing doxorubicin (DOX), paclitaxel (taxol), and mitomycin C (MMC) attached to the cathepsin B-sensitive dipeptide Phe-Lys via a self-immolative spacer were prepared as model compounds for internalizing anticancer immunoconjugates. Cathepsin B-mediated release rates of free drug, rat liver lysosomal susceptibility and human plasma stability were measured for each.
制备了通过自裂解间隔基与组织蛋白酶B敏感二肽苯丙氨酸-赖氨酸相连的含有阿霉素(DOX)、紫杉醇(紫杉醇)和丝裂霉素C(MMC)的底物,作为内化抗癌免疫缀合物的模型化合物。分别测定了组织蛋白酶B介导的游离药物释放速率、大鼠肝脏溶酶体敏感性和人血浆稳定性。